CN102532020B - 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物 - Google Patents

作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物 Download PDF

Info

Publication number
CN102532020B
CN102532020B CN201110411212.5A CN201110411212A CN102532020B CN 102532020 B CN102532020 B CN 102532020B CN 201110411212 A CN201110411212 A CN 201110411212A CN 102532020 B CN102532020 B CN 102532020B
Authority
CN
China
Prior art keywords
compound
methyl
methoxy
tumors
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110411212.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102532020A (zh
Inventor
李永福
安昌浩
赵元济
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of CN102532020A publication Critical patent/CN102532020A/zh
Application granted granted Critical
Publication of CN102532020B publication Critical patent/CN102532020B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201110411212.5A 2006-11-17 2007-11-16 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物 Expired - Fee Related CN102532020B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86626906P 2006-11-17 2006-11-17
US60/866,269 2006-11-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800425993A Division CN101573337B (zh) 2006-11-17 2007-11-16 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物

Publications (2)

Publication Number Publication Date
CN102532020A CN102532020A (zh) 2012-07-04
CN102532020B true CN102532020B (zh) 2015-02-25

Family

ID=39430327

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110411212.5A Expired - Fee Related CN102532020B (zh) 2006-11-17 2007-11-16 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物
CN2007800425993A Expired - Fee Related CN101573337B (zh) 2006-11-17 2007-11-16 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800425993A Expired - Fee Related CN101573337B (zh) 2006-11-17 2007-11-16 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物

Country Status (13)

Country Link
US (2) US8034829B2 (https=)
EP (2) EP2099765B1 (https=)
JP (2) JP5270564B2 (https=)
KR (1) KR101464591B1 (https=)
CN (2) CN102532020B (https=)
AU (2) AU2007322068B2 (https=)
BR (1) BRPI0718841A2 (https=)
CA (1) CA2669083C (https=)
ES (1) ES2392361T3 (https=)
IL (2) IL198571A (https=)
MX (1) MX2009005242A (https=)
PL (1) PL2099765T3 (https=)
WO (1) WO2008063548A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034829B2 (en) * 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
KR101641196B1 (ko) * 2014-09-18 2016-07-21 전남대학교산학협력단 헤테로아릴이소퀴놀린계 유도체 및 이를 포함하는 항암 조성물
US10341135B2 (en) * 2015-12-30 2019-07-02 Nova-Tron Controls Corp. Zone control system for conveyor system
JP7344486B2 (ja) 2018-03-30 2023-09-14 国立大学法人京都大学 心筋細胞成熟促進剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
KR20020074568A (ko) * 2001-03-20 2002-10-04 양지화학 주식회사 항암제로 유용한 3-아릴이소퀴놀린 유도체 및 그의 염
CN101573337B (zh) * 2006-11-17 2012-02-08 瑞沙恩医药公司 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788608A (fr) * 1971-09-09 1973-03-08 Koninklijke Pharma Fab Nv Aminoisoquinoleines
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
KR20020074568A (ko) * 2001-03-20 2002-10-04 양지화학 주식회사 항암제로 유용한 3-아릴이소퀴놀린 유도체 및 그의 염
CN101573337B (zh) * 2006-11-17 2012-02-08 瑞沙恩医药公司 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Medicinal Chemistry Letters》.2003,第13卷4451-4454. *
Medicinal Chemistry》.2002,第10卷2954-2956. *
Won-Jea Cho et al..Molecular Modeling of 3-Arylisoquinoline Antitumor Agents Active Against A-549.A Comparative Molecular Field Analysis Study.《Bioorganic &amp *
Won-Jea Cho et al..Synthesis of New 3-Arylisoquinolinamines:Effect on Topoisomerase I Inhibition and Cytotoxicity.《Bioorganic &amp *

Also Published As

Publication number Publication date
US20120029012A1 (en) 2012-02-02
KR101464591B1 (ko) 2014-11-27
CA2669083C (en) 2014-10-28
JP5668092B2 (ja) 2015-02-12
JP5270564B2 (ja) 2013-08-21
MX2009005242A (es) 2009-08-19
AU2012203232A1 (en) 2012-06-21
CN101573337B (zh) 2012-02-08
IL198571A0 (en) 2010-02-17
AU2012203232B2 (en) 2014-10-09
JP2010510217A (ja) 2010-04-02
CN101573337A (zh) 2009-11-04
EP2423196A1 (en) 2012-02-29
WO2008063548A3 (en) 2009-01-08
WO2008063548A2 (en) 2008-05-29
BRPI0718841A2 (pt) 2014-02-04
JP2013151546A (ja) 2013-08-08
IL198571A (en) 2013-02-28
ES2392361T3 (es) 2012-12-10
CN102532020A (zh) 2012-07-04
US8314123B2 (en) 2012-11-20
US20080182871A1 (en) 2008-07-31
AU2007322068A1 (en) 2008-05-29
IL223327A0 (en) 2013-02-03
US8034829B2 (en) 2011-10-11
AU2007322068B2 (en) 2012-07-12
EP2099765A2 (en) 2009-09-16
EP2099765B1 (en) 2012-08-29
KR20090098821A (ko) 2009-09-17
PL2099765T3 (pl) 2013-01-31
CA2669083A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
CN102532020B (zh) 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物
US9713615B2 (en) Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds
WO2013008872A1 (ja) Ｐａｒｐ阻害活性を有する新規化合物
CA2821638C (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
CN106117182B (zh) 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
CN103429586A (zh) 哌嗪二酮化合物
US20090163494A1 (en) Protein kinase inhibitors
US9403834B2 (en) Pyrrolotriazines as potassium ion channel inhibitors
CN106565599A (zh) 2‑氨甲基吡啶基烟酰胺类化合物及其制备方法和应用
KR20200142245A (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
JP2019517595A (ja) ２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミド化合物及びＰＤＫ１／ＡｕｒＡの二重阻害剤としてのそれらの使用
CN107573325A (zh) 三氮唑－n－四氢异喹啉类化合物及其制备方法和应用
IL101157A (en) History of aza- and diazea-anthracenedione N-oxides, process for their preparation and anigoidal preparations containing them
RS20060049A (sr) Novi n-supstituisani amidi indolil-3-glioksilne kiseline, njihova upotreba kao leka i postupak za njihovo dobijanje

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150225

Termination date: 20201116